Nautilus Biotechnology

NAUT

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding

In their latest 13F (Q3 2026)

See who

Value held

$0k

Combined value at quarter end

Last quarter

0 bought

1 sold or trimmed

Price at Q1 ’26 end

$3.88

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Managers holding it, by quarter

0Q4 ’23

0Q1 ’24

0Q2 ’24

0Q3 ’24

0Q4 ’24

0Q1 ’25

0Q2 ’25

0Q3 ’25

0Q4 ’25

1Q1 ’26

0Q2 ’26

0Q3 ’26

Counts the managers on this site whose 13F for that quarter includes Nautilus Biotechnology.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

No manager on this site held it in their latest 13F.

Download the holders: CSV · JSON · Markdown

About the company

Sector: Technology · Laboratory Analytical Instruments
Financial year ends: 31 December
Shares outstanding: 127m at 24 Jul 2026
SEC filings: Annual reports and other filings on EDGAR

Revenue and profit

Nautilus Biotechnology revenue and net income by year
Year	Revenue	Net income
2025	–	−$59.0m
2024	–	−$70.8m
2023	–	−$63.7m
2022	–	−$57.9m
2021	–	−$50.3m
2020	–	−$15.6m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.

Sold out last quarter

Polen Capital Management in Q2 2026